ImmunityBio, Inc. Financials

Market Capitalization $3.46 Billion as of Jan. 1, 2025

Valuations Metrics as of Jan. 25, 2025

Trailing PE	-2.76
Forward PE	-7.87
Price to Sales TTM	$471.40
Price to Book MRQ	$-2.96
Enterprise to Revenue	592.69
Enterprise to EBITDA	-12.73

Financial Reports as of Sep. 30, 2024

Financials

Fiscal Year Ends	2023-12-31
Most Recent Quarter	2024-09-30
Profit Margin	0.00%
Operating Margin	-1314.33%
Return on Assets TTM	-56.35%
Return on Equity TTM	99.53%

Income Statement

Revenue TTM	$7,332,000
Revenue per Share TTM	$0.01
Quarterly Revenue Growth	7346.30%
Gross Profit TTM	$0
EBITDA	$-341,304,000
Net Income to Common TTM	$-587,793,984
Diluted EPS TTM	$-0.90
Quarterly Earnings Growth YoY	7346.34%

Balance Sheet

Total Cash MRQ	$130,367,000
Total Cash per Share MRQ	$0.19
Total Debt MRQ	$
Total Debt to Equity MRQ	-1.37
Current Ratio MRQ	2.68
Book Value per Share MRQ	$-1.07

Cash Flow

Operating Cash Flow TTM	$-421,363,008
Levered Free Cash Flow TTM	$-288,759,872

IBRX Stock Info as of Jan. 25, 2025

Stock Statistics

Shares Outstanding	696,830,976
Float Shares	165,539,243
Avg 10 Volume	2,993,870
Avg 30 Volume	None
Shares Short	52,052,392
Short Ratio	5.76
Short % of Shares	32.20%
% Held by Insiders	77.00%
% Held by Institutions	10.11%

Stock Price Summary

Beta	-0.43
Fifty Two Week Low	$2.28
Fifty Two Week High	$10.53
Fifty Two Week Change	-15.14%
Day 50 MA	$4.52
Day 200 MA	$5.29

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date